The Pharmacy Times® Dermatology Resource Center is a comprehensive resource for clinical news and expert insights on the treatment of skin disorders, including psoriasis, atopic dermatitis, eczema, and acne.
July 25th 2024
The Lancet published data from DELTA 1 and DELTA 2 trials that displayed treatment success among individuals treated with delgocitinib cream.
Non-Melanoma Skin Cancers: The Evolution of Treatment With Immune Checkpoint Inhibitors and Its Implications f...
1.0 Credit / Oncology, Dermatology
View More
AJMC® Powered by Patients and Managed Care Insights – More Than a Cosmetic Disease: Vitiligo Treatment Approac...
1.5 Credits / Dermatology
View More
Unveiling the Impact of Childhood Eczema: A Guide to Moderate-Severe Pediatric Atopic Dermatitis
1.0 Credit / Dermatology, Immunology
View More
Revolutionizing Pediatric Atopic Dermatitis Treatment With Targeted Biologics
1.0 Credit / Dermatology, Immunology
View More
Maximizing the Potential of Biologics in Moderate to Severe Pediatric Atopic Dermatitis: The Expertise of the ...
1.0 Credit / Dermatology, Immunology
View More
Best Practices for Optimizing Biologic Therapy Management for Moderate to Severe Atopic Dermatitis in Children
1.5 Credits / Dermatology, Immunology
View More
The Evolving Treatment Paradigm of Demodex Blepharitis: Considerations for Pharmacists (Pharmacist Credit)
1.0 Credits / Ophthalmology/Optometry, Dermatology
View More
The Evolving Treatment Paradigm of Demodex Blepharitis: Considerations for Pharmacists (Pharmacy Technician Cr...
1.0 Credits / Ophthalmology/Optometry, Dermatology
View More
Child Abuse: Responsibilities and Protection of the Reporter
1.0 Credit / Law
View More
Navigating the Complexities of Biologic Therapy for Moderate to Severe Atopic Dermatitis in Children: The Impa...
1.5 Credit / Dermatology, Immunology
View More
The Role of Daily Photoprotection and Antioxidants in Sun Protection: A Guide for Pharmacists and Pharmacy Tec...
1.0 Credit / Dermatology, OTC
View More
The Role of Daily Photoprotection and Antioxidants in Sun Protection: A Guide for Pharmacists and Pharmacy Tec...
1.0 Credit / Dermatology, OTC
View More
Understanding the Role of Ceramides in Acne Management: Opportunities to Improve Clinical Outcomes
1.0 Credit / Dermatology, OTC
View More
Skin-Related Changes in Persons With Diabetes: Using Ceramides to Address Skin Barrier Dysfunction
1.0 Credit / Dermatology, OTC
View More
Skin-Related Changes in Persons With Diabetes: Using Ceramides to Address Skin Barrier Dysfunction (Pharmacy T...
1.0 Credit / Dermatology, OTC
View More
Adjunctive Therapies in Atopic Dermatitis: Understanding the Role of the Skin Barrier and Microbiome in Diseas...
1.0 Credit / Dermatology, OTC
View More
Understanding the Role of Ceramides in Acne Management: Opportunities to Improve Clinical Outcomes (Pharmacy T...
1.0 Credit / Dermatology, OTC
View More
Adjunctive Therapies in Atopic Dermatitis: Understanding the Role of the Skin Barrier and Microbiome in Diseas...
1.0 Credit / Dermatology, OTC
View More
Alleviating Patient Burden in Acne: Utilizing Ceramides to Address Skin Barrier Dysfunction
0.75 Credit / Dermatology, OTC
View More
Alleviating Patient Burden in Acne: Utilizing Ceramides to Address Skin Barrier Dysfunction (Pharmacy Technici...
0.75 Credit / Dermatology, OTC
View More
Treatment Gaps in the Management of Generalized Pustular Psoriasis: Enhancing the Role of Managed Care
1.5 Credits / Dermatology, Immunology
View More
Advancing Patient Outcomes in Hidradenitis Suppurativa: Updates and Strategies for Managed Care
1.5 Credits / Dermatology
View More
Examining Patient Burden in Atopic Dermatitis: Understanding Treatment Barriers and Optimal Use of OTC Skin Ca...
0.5 Credit / Dermatology, OTC
View More
Examining Patient Burden in Atopic Dermatitis: Understanding Treatment Barriers and Optimal Use of OTC Skin Ca...
0.5 Credit / Dermatology, OTC
View More
Phase 3 Data Favor Bimekizumab Over Placebo in Biologic-Naïve Patients With Psoriatic Arthritis
December 20th 2022All primary and ranked secondary endpoints of the study were met at week 16, which were sustained or improved through week 24 and were coupled with patient-reported improvements compared with placebo in treating psoriatic arthritis.
Read More
Lebrikuzumab Found to Maintain Durable Skin Clearance When Dosed Every 4 Weeks in Atopic Dermatitis
September 14th 2022ADvocate 1 and ADvocate 2 are 52-week randomized, double-blind phase 3 studies designed to evaluate lebrikizumab as monotherapy in adult and adolescent patients with moderate to severe AD.
Read More
FDA Approves Citrate-Free High-Concentration Humira Biosimilar Hadlima
August 18th 2022Adalimumab-bwwd is a tumor necrosis factor blocker indicated for rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn disease, ulcerative colitis, and plaque psoriasis.
Read More